We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current TWAPF market cap is 1.2B. The company's latest EPS is JPY 328.5733 and P/E is 0.07.
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Revenue | 110.38B | 154.9B | 165.62B | 208.86B | 227.93B |
| Operating Income | 12.84B | 19.93B | 19.21B | 5.08B | 17.65B |
| Net Income | 11.2B | 13.96B | 15.91B | 2.2B | 16.17B |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Assets | 228.14B | 245.67B | 329.94B | 371.35B | 430.65B |
| Total Liabilities | 123.49B | 129.07B | 197.77B | 234.45B | 274.76B |
| Total Equity | 104.65B | 116.6B | 132.17B | 136.89B | 155.89B |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Operating | 19.16B | 12.01B | 22.13B | 2.54B | 8.22B |
| Investing | -39.54B | -9.1B | -59.73B | -30.28B | -40.39B |
| Financing | 11.75B | 187M | 46.54B | 17.48B | 35.41B |
| Market Cap | 1.2B |
| Price to Earnings Ratio | 0.07 |
| Price to Sales Ratio | 0.01 |
| Price to Cash Ratio | 0.04 |
| Price to Book Ratio | 0.01 |
| Dividend Yield | - |
| Shares Outstanding | 49.22M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 18.88 (52.66%) |
| Company Name | Towa Pharmaceutical Company Ltd (PK) |
| Address |
2-11 shinbashi-cho kadoma, osaka 571-8580 |
| Website | https://www.towayakuhin.co.jp |
| Industry | pharmaceutical diversified (H2) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
